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Abstract 
Image-guided and target-selective modulation of drug delivery by external physical triggers at the 
site of pathology has the potential to enable tailored control of drug targeting. Magnetic 
microbubbles that are responsive to magnetic and acoustic modulation and visible to 
ultrasonography have been proposed as a means to realize this drug targeting strategy. To comply 
with this strategy in vivo, magnetic microbubbles must circulate systemically and evade deposition in 
pulmonary capillaries, while also preserving magnetic and acoustic activities in circulation over time. 
Unfortunately, challenges in fabricating magnetic microbubbles with such characteristics have 
limited progress in this field. In this report, we develop magnetic microbubbles (MagMB) that display 
strong magnetic and acoustic activities, while also preserving the ability to circulate systemically and 
evade pulmonary entrapment.  
Methods: We systematically evaluated the characteristics of MagMB including their 
pharmacokinetics, biodistribution, visibility to ultrasonography and amenability to magneto-acoustic 
modulation in tumor-bearing mice. We further assessed the applicability of MagMB for 
ultrasonography-guided control of drug targeting. 
Results: Following intravenous injection, MagMB exhibited a 17- to 90-fold lower pulmonary 
entrapment compared to previously reported magnetic microbubbles and mimicked circulation 
persistence of the clinically utilized Definity microbubbles (>10 min). In addition, MagMB could be 
accumulated in tumor vasculature by magnetic targeting, monitored by ultrasonography and 
collapsed by focused ultrasound on demand to activate drug deposition at the target. Furthermore, 
drug delivery to target tumors could be enhanced by adjusting the magneto-acoustic modulation 
based on ultrasonographic monitoring of MagMB in real-time.  
Conclusions: Circulating MagMB in conjunction with ultrasonography-guided magneto-acoustic 
modulation may provide a strategy for tailored minimally-invasive control over drug delivery to 
target tissues. 
Key words: theranostics, magnetic microbubbles, lung evading microparticles, image-guided drug delivery, 
remote-controlled drug delivery. 
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Introduction 
Efficient systemic drug therapy for cancer and 
other intractable diseases requires delivery of 
therapeutically effective drug concentrations to the 
site of pathology at safe systemic doses. A wide 
variety of drug carriers have been designed to target 
diseased tissues by leveraging cell-specific ligands or 
tumor vascular abnormalities [1]. However, the 
stochastic nature of these approaches and the high 
heterogeneity of pathologies, particularly in cancer, 
compromise attainment of desired drug levels at the 
target [1, 2]. 
An emerging therapeutic strategy of theranostics 
that combines therapeutic and diagnostic components 
in a single system has the potential to address this 
challenge by tailoring delivery of therapeutics to each 
patient’s disease state [3, 4]. The key to this strategy is 
multi-modality drug carriers that can be 
simultaneously visualized by non-invasive imaging 
and modulated by external physical triggers to allow 
localized tuning of drug delivery selectively at the 
target. Among investigated agents, lipid-shelled 
microbubbles utilized clinically as contrast agents for 
diagnostic ultrasonography provide several unique 
advantages [5]. Lipid-shelled microbubbles are 
compressible microparticles composed of a gaseous 
core coated with a thin lipid film. These systemically 
circulating agents can be visualized by 
ultrasonography and collapsed by focused ultrasound 
selectively in target tissues to simultaneously release 
the drug cargo and promote drug uptake by tissues 
[6]. However, standard microbubble formulations 
lack mechanisms for preferential accumulation in 
target tissues, rendering drug delivery by 
microbubbles and ultrasound largely inefficient [7]. 
Ligand-based methods have been explored to target 
microbubbles to specific sites [8], but paucity of 
tissue-specific biomarkers and immunogenicity of 
targeting ligands limit their potential for drug 
delivery [1, 7-9]. 
As an alternative, a large body of research in 
recent years has focused on the development of 
magnetic microbubbles [7, 10, 11]. Magnetic 
microbubbles are multi-scale composites of 
microbubbles and superparamagnetic iron oxide 
nanoparticles - agents that endow the microbubbles 
with magnetic responsiveness. Because magnetic 
microbubbles possess dual sensitivity to ultrasound 
and magnetic fields, they can, in principle, combine 
the advantages of both traditional microbubbles and 
magnetic drug carriers. Magnetic microbubbles have 
been envisioned to be concentrated in target tumor 
vasculature by magnetic fields, monitored by 
ultrasonography to ascertain delivery and activated 
by ultrasound to facilitate drug release and 
extravasation [12]. Because modulation by magnetic 
fields and ultrasound can be tailored on demand 
based on ultrasonography information, this 
multi-modality targeting paradigm could provide a 
means to control drug doses delivered to the target. 
However, formulating magnetic microbubbles 
for in vivo magneto-acoustic drug delivery remains a 
considerable challenge. Magnetic microbubbles must 
display high magnetic and acoustic sensitivities, while 
also preserving the ability to circulate systemically 
and access the vasculature of target tissues. 
Unfortunately, microbubble designs that maximize 
their magnetic activity also impose structural changes 
that compromise the microbubbles’ acoustic 
properties and circulation stability. [11, 13, 14] To 
obtain microbubbles with high magnetic 
responsiveness, iron oxide nanoparticles have been 
incorporated into the shell of polymer- and 
lipid-shelled microbubbles, encapsulated in oil-layers 
of acoustically active lipospheres or attached to the 
microbubble’s surface using avidin/streptavidin- 
biotin linkers. [11, 15-19] However, integration of 
rigid nanoparticles into the microbubble’s shell 
stiffens the microbubbles, reducing their sensitivity to 
ultrasound, [11, 13, 20] while decoration of the 
microbubble surface with immunogenic ligands leads 
to complement activation and surface destabilization 
by complement components [21]. Both the surface 
destabilization and the stiffening effects increase the 
undesirable propensity for microbubble entrapment 
in lung capillaries, [22, 23] leading to first-pass 
pulmonary clearance of a significant fraction of the 
dose (17-90%) [11, 14, 18, 24]. Pulmonary entrapment 
not only prevents the microparticles from reaching 
the vasculature of peripheral target tumors, but it also 
poses risks of vascular occlusion and life-threatening 
thromboembolic toxicity [25]. Clinically used 
lipid-shelled microbubbles (e.g., Definity) successfully 
evade entrapment in the lungs and remain in 
circulation for 5-10 min, providing sufficient vascular 
exposure for imaging or modulation by external 
triggers [26, 27]. However, emulating this behavior 
with multi-scale nanoparticle-carrying magnetic 
microbubbles remains a considerable challenge. 
Here, we develop magnetic microbubbles that 
mimic the in vivo behavior of clinically-utilized 
lipid-shelled microbubbles (e.g., Definity), while also 
displaying sufficient magnetic and acoustic 
sensitivities for magneto-acoustic modulation. The 
advantageous in vivo behavior of Definity-like 
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microbubbles has been ascribed to their inherent 
compressibility and surface protection by flexible 
hydrophilic polymers, termed stealth coatings [5, 26]. 
We sought to develop magnetic microbubbles with 
similar attributes. It is known that fabrication of 
nanoparticle-microbubble composites by attaching 
nanoparticles to the microbubble’s surface can 
preserve the original microbubble’s compressibility 
[28]. It is also known that heparin, a clinically utilized 
non-immunogenic anionic polysaccharide, can impart 
stealth properties to the drug carrier’s surface. [29] We 
considered that attaching heparin-functionalized iron 
oxide nanoparticles to the surface of lipid-shelled 
microbubbles could preserve the compressibility of 
the microbubbles, while also providing their surface 
with stealth heparin coating. To realize these 
materials, we developed a methodology based on 
complexation of heparin with protamine, an 
arginine-rich cationic polypeptide that is clinically 
used as heparin’s antidote because of its remarkably 
high affinity (Keq = 1-20 × 107 M-1) for heparin [30]. By 
coupling heparinized magnetic nanoparticles to the 
protamine-functionalized microbubble surface, we 
fabricated circulation-stable magnetic microbubbles 
(MagMB) with strong magnetic and acoustic 
activities. We demonstrate that MagMB circulated 
systemically, evaded lung entrapment, and could be 
magnetically retained in tumor vasculature, 
monitored by ultrasonography and collapsed by 
ultrasound on demand. We further demonstrate that 
MagMB could be leveraged to enhance drug delivery 
to target tumors by real-time adjustment of 
magneto-acoustic drug targeting based on 
ultrasonographic monitoring of the carriers. 
Materials and Methods 
Materials 
Lipids including 1,2-distearoyl-sn-glycero-3- 
phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3- 
phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (DSPE-mPEG(2kDa)) and 1,2-distearoyl- 
sn-glycero-3-phosphoethanolamine-N [maleimide 
(polyethylene glycol)-2000] (ammonium salt) 
(DSPE-PEG(2kDa)-MAL) were obtained from Avanti 
Polar Lipids and used without further purification. 
Hetero-bifunctional cross-linker N-Succinimidyl 
3-[2-pyridyldithio]-propionate (SPDP) was obtained 
from Pierce. 
Synthesis of Pl-PEG-Prot conjugate 
Protamine (5 mg/mL in 100 mM phosphate 
buffer, pH 7.4) was reacted with a five-fold molar 
excess of SPDP (dissolved in dimethyl sulfoxide 
(DMSO)) for 2 h at room temperature. The coupling 
was quantified with pyridine-2-thione 
spectrophotometric assay, calibrated with free 
pyridine-2-thione in the range of 20-100 µM. The 
Protamine-PDP product was then reacted with the 
reducing agent Tris(2-carboxyethyl) phosphine 
hydrochloride (TCEP-HCL, 50mM) for 2 h to obtain 
thiolated protamine (Protamine-SH). The sulfhydryl 
content of the activated Protamine-SH was quantified 
by Ellman assay, using a well-established procedure 
[31]. To produce the conjugate (Pl-PEG-Prot), 
Protamine-SH was incubated with DSPE-PEG(2kDa)- 
MAL (1.5:1 molar ratio, 100 mM phosphate buffer, pH 
7.4) at room temperature overnight. Conjugation was 
confirmed by MALDI-TOF (MicroFlex MALDI-TOF, 
Bruker) mass spectroscopic analysis (m/z: ~7400 for 
DSPE-PEG(2 kDa)-Protamine).  
Preparation of MagMB 
Protamine-bearing microbubbles (MB-Prot), 
comprising octafluoropropane (C3F8, Synquest lab, 
FL) gas core and phospholipids/ Pl-PEG-Prot shell, 
were prepared by a high-shear emulsification method 
[32, 33]. The composition of the microbubble 
formulation mixture was DSPC: DSPE-PEG(2kDa): 
Pl-PEG-Prot (82:18-x:x, mol% ), where x is a mol% of 
Pl-PEG-Prot conjugate. The microbubbles were 
purified by several flotation (300 rcf)/ redispersion 
cycles to remove the unincorporated lipids. Protamine 
incorporation into microbubbles was confirmed by 
the Bicinchoninic acid protein assay (BCA, Pierce). 
Microbubbles were quantified using the Coulter 
Counter (Beckman). 
Iron oxide nanoparticles coated with heparin 
were obtained from Chemicell (Germany). The 
heparinized nanoparticles (MNPh) exhibited a 
multi-crystalline core, hydrodynamic diameter of 
~122 nm and ζ – potential of -33 mV, as previously 
described [34, 35]. Nanoparticle preparations were 
quantified with Inductively Coupled Plasma Optical 
Emission Spectrometry (ICP-OES) [36]. 
Magnetic microbubbles (MagMB) were prepared 
by mixing the suspension of protamine-functionalized 
microbubbles (MB-Prot) with the suspension of the 
heparinized nanoparticles (MNPh), followed by two 
purification steps. In the first step, a combination of 
gravity separation and centrifugation was used to 
remove large microbubbles and non-attached 
nanoparticles [37, 38]. The microbubble suspension 
was first left to stand for 5 min at room temperature to 
allow flotation of large microbubbles (>8 µm).[38] The 
remaining suspension (infranate) was decanted and 
centrifuged (300 rcf) to collect all remaining 
microbubbles into a cake layer. The respective 
infranate was discarded to remove non-attached 
nanoparticles. In the second step, the cake layer was 
reconstituted with PBS and placed on a magnetic 
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separator. The fraction that migrated to the magnet 
(MagMB) was collected and the non-magnetic fraction 
discarded. Representative microbubble size 
distributions and counts obtained during the 
purification procedure are provided in Figure S3. 
Typical yields of purified MagMB relative to the 
initial counts of MB-Prot were 30-35%. 
Characterization of MagMB 
Morphological characterization 
Morphological characterization of MagMB was 
conducted using bright field optical microscopy 
(Axiovert 200M, Zeiss), transmission electron 
microscopy (TEM, JEOL JEM 200CX) and cryoTEM 
(Jeol 2100 FEG TEM, equipped with the Single Tilt 
Liquid Nitrogen Cryo-Transfer Holder, Gatan). For 
optical microscopy, samples of aqueous microbubble 
suspension were spotted on a glass slide, 
coverslipped and imaged through the coverslip using 
20x (air) and 100x (oil) objectives. For TEM, samples of 
aqueous microbubble suspension were spotted onto a 
holey carbon-film coated grid (CF200-Cu, EMS) and 
allowed to dry at room temperature. For cryoTEM, 
samples of aqueous microbubble suspension were 
spotted onto a holey carbon-film coated grid 
(Quantifoil R5/20) and immersion-frozen with the 
semi-automatic cryo-plunger (CryoPlunge3, Gatan). 
The size distribution of MagMB was analyzed with 
Multisizer 3 Coulter Counter (Beckman Coulter). The 
zeta potential was analyzed by phase analysis light 
scattering using ZetaPALS (Brookhaven). 
Nanoparticle loading 
For quantitative analysis of MNPh loading, 
MagMB were disrupted by brief sonication and 
MNPh quantified by ICP-OES as previously described 
[36]. Amounts of MNPh in microbubble samples were 
normalized by the microbubble counts. 
Magnetic capture assay 
The analysis of the magnetic properties of 
MagMB was conducted with a dynamic flow assay 
[36]. The microbubble samples were infused at linear 
flow rates of 0.04-0.7 cm/s through a capillary tubing 
(ID = 0.58 mm) exposed to a magnetic field. The 
applied magnetic field was adjusted to 0.9 T (test, 
grad B = 50 T/m) or 0 T (control). The microbubble 
counts in the feed and the collector reservoirs were 
determined by the Coulter Counter (Beckman). The 
percent of the magnetically captured microbubbles 
was plotted as a function of the flow rate. 
Acoustic destructibility assay 
To assess the acoustic destructibility, 
microbubbles (107/mL) were subjected to 1 MHz 
sinusoidal tone-bursts of acoustic insonation for 0-80 s 
with the following parameters: pulse duration (PD) – 
33 µs, pulse repetition frequency (PRF) – 3 kHz and 
peak negative pressure (PNP) – 0.22 MPa. Similar 
insonation conditions have been previously utilized to 
enhance drug delivery by ultrasound-mediated 
microbubble destruction. [39-42] The acoustic setup 
(Figure 4, A1) comprised a single-element 1 MHz 
ultrasound transducer (25 mm aperture, 55 mm focal 
length: Precision Acoustics, UK) mounted in a water 
tank and driven by a wavefunction generator 
(Tektronix) and a 50 dB radio-frequency amplifier 
(ENI). [32] The sample chamber (2 mL) sealed at the 
top and the bottom with the Mylar membrane was 
pre-filled with degassed PBS. Microbubble samples 
were injected through a side port and re-dispersed in 
PBS. The sample chamber was submersed in the water 
tank and secured at the focal length from the face of 
the transducer. The acoustic pressure at the sample 
plane was calibrated with a 0.5 mm needle 
hydrophone (Precision Acoustics, UK) connected to a 
PC oscilloscope (PicoScope 4224, Pico Technology). 
Following acoustic insonation (0-80 s), the residual 
microbubble counts were quantified with the Coulter 
Counter. Post insonation counts were normalized by 
the 0 s insonation counts (defined as 100%). To 
determine the microbubble half-life under acoustic 
insonation, an exponential decay model y = Ae-x/t was 
fitted to the data sets of normalized post-insonation 
counts over time using OriginPro9. 
Serum stability 
The microbubble composites were tested for 
serum stability. Purified, nanoparticle-loaded 
microbubble samples engrafted with MNPh (20±3 fg 
Fe/µm2) were re-dispersed in either fetal bovine 
serum (FBS, 50%) or PBS. Following incubation at 
room temperature for 30 min, the microbubbles were 
collected by flotation, counted, disrupted by brief 
sonication and analyzed for content of MNPh as 
described above. 
In vivo studies 
All animal procedures were approved by the 
MIT and the University of Michigan Institutional 
Committees on Animal Care. 
Establishment of subcutaneous tumors in mice 
Murine LL/2 Lewis lung carcinoma cells (ATCC: 
CRL-1642) were grown as monolayers in DMEM 
media supplemented with 10% fetal bovine serum. 
For implantation, the cells were harvested by 
trypsinization (0.25% Trypsin-EDTA, Gibco) and 
resuspended in sterile PBS at 2 x 107 cell / mL. 
Tumors were established in the rear flank of 6- to 
8-week-old SCID mice (SHO, Charles River) by 
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subcutaneous injection of cell suspension (50 µL, 1 x 
106 cells). Tumors were allowed to grow for 7-14 days 
to a volume of ~500 µL.  
Biodistribution analysis 
For biodistribution analysis, the microbubbles 
were labeled with the near-infrared dye Cy5.5 
through incorporation of DSPE-PEG(2kDa)-Cy5.5 
(0.1% of lipid composition). Microbubble suspensions 
(MagMB-Cy5.5, 100 µL, 1 x 109 /kg) were 
administered to mice intravenously, via catheterized 
lateral tail-vein. The biodistribution was assessed by 
the whole-body fluorescence imaging and by ex vivo 
organ analysis. Fluorescence imaging (excitation/ 
emission at 640 nm/720 nm, epi-illumination mode) 
was conducted using IVIS Spectrum imaging system 
(Xenogen). Animal organs were harvested, 
flash-frozen in liquid nitrogen and stored at -80°C 
until analysis.  
In vivo echogenicity and pharmacokinetic analysis by 
ultrasonography 
Real-time image-monitoring of microbubbles 
was performed with the high-frequency ultrasound 
imaging system (Vevo 770®, Visual Sonics) equipped 
with a 30 MHz linear transducer RMV-707B (Visual 
Sonics). The transducer had a lateral and axial 
resolution of 115 µm and 55 µm, respectively, and a 
focal length of 12.7 mm. The geometric focus of the 
transducer was aligned with the renal artery. A solid 
gel standoff of ~5-7 mm thickness (Aquaflex 
ultrasound gel pad, Parker lab) and the ultrasound 
transmission gel (Aquasonic-100, Parker lab) were 
used to provide acoustic coupling. The images were 
acquired over a field of view of 12 mm x 12 mm using 
20% transmit power. 
The microbubble suspension (100 µL) was 
administered via the catheterized lateral tail vein by 
an i.v. bolus injection. The doses of 7.5 x 107 /kg and 1 
x 109 /kg were used for analyses of in vivo 
echogenicity and pharmacokinetics, respectively. 
Similar doses were previously used in diagnostic and 
therapeutic studies, respectively. [41, 43, 44] 
Microbubble perfusion through the organ of interest 
(renal artery) was monitored by sequential acquisition 
of two-dimensional, fundamental-frequency B-mode 
scans. For pharmacokinetic monitoring, scans were 
acquired before, during and post injection at a 30-50 
Hz frame rate for the first 60 s and then sequentially at 
60 s intervals. 
Magneto-acoustic targeting 
Targeting setup 
Targeting experiments were conducted with an 
in-house-assembled magneto-acoustic targeting setup 
(Figure 6, A1). A DC magnetic field (Figure 6, A3) was 
generated by a dipole electromagnet (GMW 
Associates, CA). Acoustic insonation was produced 
with a 1 MHz, focused ceramic transducer (25 mm 
diameter, 55 mm focal length) actuated in tone-bursts 
as described in section “Acoustic destructibility 
assay”. Animals were aligned on a platform with their 
tumor positioned within the airgap between the 
magnet poles. The 1 MHz transducer and the 30 MHz 
imaging probe were aligned orthogonally to the 
airgap plane and to one another. The geometric focus 
of the imaging probe (30 MHz) was positioned at the 
tumor mid-plane (Figure 6, A2 and A4). A solid gel 
standoff of a ~7 mm thickness (Aquaflex ultrasound 
gel pad, Parker lab) and the ultrasound transmission 
gel (Aquasonic-100, Parker lab) were used to provide 
acoustic coupling. Mice were administered with 
microbubbles via catheterized lateral tail-vein, and 
microbubble perfusion through the organ of interest 
(tumor vasculature) was monitored by 
ultrasonography as described in section “In vivo 
echogenicity and pharmacokinetic analysis by 
ultrasonography”. Each animal received a single 100 
µL bolus injection of microbubbles (1 x 109 /kg) 
during the course of an experiment. The tumors were 
exposed to the magnetic targeting (field and gradient 
of 0.9 T and 50 T/m, respectively) and ultrasound 
insonation (the Ultrasound Targeted Microbubbles 
Destruction or UTMD protocol: PNP = 0.22 MPa, PRF 
= 3 kHz, PD = 33 µs).  
Study design for testing magneto-acoustic modulation 
of MagMB 
The behavior of MagMB in tumors under 
magneto-acoustic modulation (magnetic targeting + 
UTMD) was tested in two groups of mice. Both 
groups received a single i.v. bolus injection of MagMB 
(100 µL, 1 x 109 /kg). The test group was exposed to 
magnetic targeting for 30 min, and thereafter, to 
UTMD for 50 s at 40 min post microbubble 
administration. No physical forcefields were applied 
on the interval of 30-40 min post microbubble 
administration. The control group was not subjected 
to physical forcefields. The time-line of treatment 
administration is depicted in Figure 6, B. 
Study design for testing drug delivery 
In vivo delivery of a model drug Cy5.5 to tumors 
using MagMB-Cy5.5 was tested in seven groups of 
mice. Each group received a single i.v. bolus injection 
of MagMB-Cy5.5 (100 µL, 1 x 109 /kg) and was 
subjected to one of the following treatments: (1) (MF-, 
US-) no magnetic targeting or UTMD, (2) (MF+, US-) 
magnetic targeting only, (3) (MF-, US+) UTMD only, 
(4) (MF+, US+) combination of magnetic targeting and 
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UTMD. For treatments 2-4, magnetic targeting was 
applied for 1 min or 5 min, immediately followed by 
UTMD for 50 s at 1 min or 5 min post microbubble 
administration, respectively. At 120 min 
post-treatment, the delivery of the model drug (Cy5.5) 
to tumors was quantified by fluorescence imaging as 
described in section “Biodistribution analysis”. The 
time-line of treatment administration and drug 
delivery assessment is depicted in Figure 7, A. 
Ex vivo analysis 
Quantitative analysis of the microbubble 
biodistribution was conducted according to our 
previously reported procedure.[32] Briefly, mouse 
organs were cryogenically ground with the 
Geno/Grinder (Spex), extracted with the Glo lysis 
buffer (Promega), and analyzed for fluorescence 
intensity using fluorescence spectroscopy 
(excitation/emission at 640nm/710nm).  
Image analysis 
Ultrasound imaging 
Video intensity ultrasound data were analyzed 
using custom software developed with the Matlab 
R2015 software package. To assess kinetics of 
microbubble transit and microvascular retention, 
microbubble-dependent contrast enhancement (CE) 
within the region of interest (ROI) was calculated at 
image-monitored time points (t) in two steps. First, CE 
at time t was calculated as a difference between the 
post-injection image frame at time t and the 
background signal averaged over 50-100 consecutive 
pre-injection frames. Then, CEROI(t) was calculated as 
the average CE(t) pixel intensity within the ROI 
drawn to outline the relevant area (the renal artery 
(RA) or tumor area (T)) on the B-mode scan. CEROI(t) 
values were plotted as a function of time to generate 
time-intensity curves. To allow for averaging of 
time-intensity curves from different subjects while 
accounting for variation in image acquisition time 
points, linear interpolation was applied to the data 
sets.  
The in vivo echogenicity of microbubbles was 
quantified as the peak signal enhancement of the renal 
artery by microbubbles (7.5 x 107 /kg, 100 µL, i.v. 
bolus) normalized by the pre-injection renal artery 
baseline. The in vitro echogenicity was quantified as 
the signal enhancement generated by suspending 
microbubbles in PBS (106 /mL) normalized by the 
respective PBS baseline. 
Fluorescence in vivo imaging 
Fluorescence image analysis was conducted with 
the Living Image 4.4 software package. The ROI was 
drawn to outline the relevant area on the whole-body 
or individual organ scans. Tumor ROI data were 
offset by blank controls. Tumor ROIs of animals 
imaged under the same fluorescence conditions as the 
test mice but not exposed to MagMB-Cy5.5 were used 
as blank controls. 
Statistical analysis 
Data are expressed as mean ± SD unless 
otherwise specified. Comparisons between 2 groups 
were made using the unpaired t-test. Means of 
multiple groups were compared with the 1-way 
ANOVA, followed by post hoc Tukey’s pairwise 
comparisons. The acoustic destruction data for 
different microbubble samples were compared 
through curve fitting analysis. An exponential decay 
model was first fitted globally to concatenated 
datasets and then separately to individual data sets of 
microbubble counts over time. The goodness-of-fit 
was compared using the extra-sum-of-squares F test. 
All probability values are 2-sided, and values of 
p<0.05 were considered statistically significant. Curve 
fitting and statistical analyses were carried out using 
OriginPro9 (OriginLab) and SPSS (IBM) software 
packages. 
Results and Discussion 
Fabrication and optimization of magnetic 
microbubbles  
To assemble magnetic microbubbles, we 
developed a two-step methodology (Figure 1, A.a). 
We first prepared protamine-functionalized 
microbubbles (MB-Prot, Figure 1, A.a – step i) and 
then attached heparin-functionalized magnetic 
nanoparticles (MNPh) to the surface of MB-Prot 
(Figure 1, A.a – step ii). To prepare MB-Prot, we 
synthesized an amphiphilic phospholipid-PEG- 
protamine conjugate (PL-PEG-Prot, Figure 1, A.b). We 
reasoned that the amphiphilic conjugate would 
self-insert into the phospholipid microbubble shell 
and allow protamine to display on the microbubble’s 
surface. Indeed, the PL-PEG-Prot conjugate could be 
integrated into microbubbles by adding PL-PEG-Prot 
to the microbubble’s lipid formulation. The 
conjugate-modified microbubbles displayed 
significantly higher protamine content and a 
significantly higher zeta potential compared to 
controls (Figure 1, B-C, p<0.001). These findings 
confirmed insertion of PL-PEG-Prot into the 
microbubble’s shell and the display of cationic 
protamine on the microbubble’s surface, respectively. 
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Figure 1. Fabrication of magnetic microbubbles. (A) a. Scheme of the two-step assembly of magnetic microbubbles – step I: preparation of 
protamine-functionalized microbubbles; step II: coupling of protamine-functionalized microbubbles with heparin-coated iron oxide nanoparticles. (A) b. Structure of 
PL-PEG-Prot conjugate comprising (1) lipid membrane anchor, (2) poly(ethylene glycol) 2 kDa spacer, and (3) protamine. (B) Analysis of protamine concentrations in 
microbubble samples incubated with free protamine and PL-PEG-Prot. Data represent mean ± SD, n = 4. (C) Zeta potential of MB-cnt and MB-Prot dispersed in PBS, 
pH 7.4. Data represent mean ± SD, n = 4. (D) Analysis of MNPh loading in control MB-cnt and protamine-functionalized microbubbles MB-Prot. Data represent mean 
± SD, n = 4. Statistical comparisons are based on unpaired t-test. Asterisks denote statistically significant differences: *p < 0.05, **p < 0.01, ***p < 0.001. MB: 
microbubbles; MB-Prot: microbubbles functionalized with protamine; MNPh: magnetic nanoparticles coated with heparin; PBS: phosphate buffered saline; PEG: 
poly(ethylene glycole); PL: phospholipid; Prot: protamine.  
 
Subsequently, we tested the feasibility of 
attaching heparinized nanoparticles (MNPh) to the 
surface of protamine-functionalized microbubbles. To 
assemble nanoparticles-microbubble composites we 
simply mixed MNPh with MB-Prot. Significantly 
higher loading of MNPh (p<0.001) was achieved by 
mixing of MNPh with protamine-functionalized 
microbubbles than with protamine-free control 
microbubbles (Figure 1, D). These findings 
corroborated the viability of heparin-protamine 
complexation as a means of forming nanoparticles- 
microbubble composites (MB-Prot/MNPh). 
Next, we carried out optimization of composite 
microbubbles. First, to display heparin as a surface 
coating on the microbubble’s surface we sought to 
saturate pendant protamine chains of MB-Prot with 
heparin-carrying nanoparticles. To achieve that, we 
performed optimization of nanoparticle loading onto 
the microbubble’s surface by mixing MB-Prot samples 
(0.22±0.03 fg protamine per µm2 surface area) with 
increasing concentrations of MNPh. The amount of 
nanoparticles attached to the microbubble’s surface 
increased with increasing mixing ratios of MNPh to 
MB-Prot and reached a plateau at 400 fg Fe/ MB 
(Figure 2, A1). Notably, the increased nanoparticle 
loading was mirrored by a corresponding reduction 
in zeta-potential (Figure 2, A2). The zeta potential of 
the cationic MB-Prot (12±2 mV) gradually decreased 
with increasing loading of MNPh and reached 
electronegative potential (-11±2 mV) for 
nanoparticle-saturated MB-Prot/MNPh composites. 
Reversal of zeta potential at saturation reflected 
successful masking of cationic protamine on the 
microbubble’s surface by anionic heparin-carrying 
nanoparticles. 
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Figure 2. Optimization of surface and magnetic properties of magnetic microbubbles. (A) Dependence of MNPh nanoparticle content (A1) and zeta 
potential (A2, PBS, pH 7.4) of the nanoparticles-microbubble composites on nanoparticle-to-microbubble incubation ratios. Data represent mean ± SD, n = 4. (B) 
Dependence of microbubble loading with MNPh nanoparticles on the protamine content of microbubbles MB-Prot. Data were fitted to a linear model, R2 = 0.99, p 
= 0.002. (C). Capture of microbubbles by an applied magnetic field (B = 0.9 T, grad B = 50 T/m) under physiological flow conditions. Inset: Schematic depiction of the 
setup for dynamic magnetic capture assay. Statistical analysis for each flow rate is based on a one-way ANOVA, followed by post hoc Tukey’s pairwise comparisons. 
Asterisks denote statistically significant difference versus MB-cnt group, *p < 0.05, **p < 0.01, ***p < 0.001. ANOVA: analysis of variance; SD: standard deviation; PBS: 
phosphate buffered saline; MB: microbubbles; MB-Prot: microbubbles functionalized with protamine; MNPh: magnetic nanoparticles coated with heparin.  
 
We then began optimization of the 
microbubble’s magnetic properties (Supplementary 
Material, Sections 1-2). Our theoretical analysis 
suggested that an estimated magnetic force threshold 
of 2x10-12 N would be required to capture a magnetic 
microsphere (~3 µm) at a characteristic capillary flow 
rate of solid tumors (~0.04 cm/s, Figure S1). The 
magnetic force exerted on a magnetic sphere depends 
on the magnetic moment of the sphere and the 
gradient of magnetic field. Considering a practically 
attainable magnetic field gradient of 50 T/m, we 
sought to prepare microbubbles with a magnetic 
moment of >4×10-14 Am2. To tune the magnetic 
moment of microbubbles, we varied the loading of 
magnetic nanoparticles (MNPh) per microbubble. 
This could be achieved by varying the density of 
protamine on the microbubble’s surface. Quantitative 
analysis revealed a positive linear correlation between 
the extent of nanoparticle loading and the protamine 
surface density of MB-Prot (R = 0.99, p = 0.002, Figure 
2, B). Microbubbles with nanoparticle loadings of 7±1 
fg/µm2 (MB-Prot/MNPh-s1), 11±1 fg/µm2 
(MB-Prot/MNPh-s2) and 17±2 fg Fe/µm2 
(MB-Prot/MNPh-s3) could be prepared using 
protamine surface densities of 0.22±0.03 fg/µm2, 
0.32±0.04 fg/µm2 and 0.42±0.04 fg/µm2, respectively. 
The microbubble sample MB-Prot/MNPh-s3 had an 
estimated magnetic moment of 4.3×10-14 Am2, which 
fulfilled the theoretical magnetic capture requirement.  
We tested the amenability of these microbubble 
samples to magnetic capture using a dynamic capture 
assay. Magnetic (B = 0.9 T, grad B = 50 T/m) capture 
of microbubbles was tested under physiologically 
relevant flow conditions using non-magnetic, 
protamine-free microbubbles (MB-cnt) as a control. At 
a tumor-mimicking flow rate of 0.04 cm/s, a major 
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fraction of MB-Prot/MNPh-s3 microbubbles (82±3%) 
was amenable to magnetic capture, while only a 
minor fraction of MB-Prot/MNPh-s2 and MB-Prot/ 
MNPh-s1 could be captured under the same 
conditions (Figure 2, C). Notably, MB-Prot/MNPh-s3 
could be captured to a significantly higher extent than 
the non-magnetic control microbubbles (MB-cnt) at 
flow rates of up to 3 cm/s (for 3 cm/s, MB-Prot/ 
MNPh-s3: 23±3% vs. MB-cnt: 5±3%, p<0.001). These 
results suggested that MB-Prot/MNPh-s3 could be 
amenable to in vivo magnetic capture. The optimized 
MB-Prot/MNPh-s3 microbubble preparation was 
termed MagMB and used in all subsequent studies. 
MagMB exhibited a narrow size distribution 
(Figure 3, A) with a mean volume-weighted diameter 
of 3.1±1.4 µm, similar to Definity (3.99 µm [38]). The 
electronegative zeta potential of MagMB (-19±4 mV) 
confirmed that heparin was displayed on the 
microbubble surface. Microbubble characterization 
using bright-field phase contrast microscopy and 
transmission electron microscopy further 
corroborated the association of MNPh with the 
microbubbles (Figure 3: B, C-I and C-II). CryoTEM 
micrographs also confirmed the attachment of the 
nanoparticles to the microbubble’s surface (Figure 3: 
C-III and C-IV). Importantly, incubation of MagMB 
with fetal bovine serum (FBS 50%, 30 min) did not 
significantly affect their MNPh content compared to 
incubation with PBS (FBS: 16±3 fg/µm2 vs. PBS: 17±2 
fg/µm2, p = 0.07, Figure 3,D). Stability of MagMB in 
the presence of serum suggested that they would be 
stable in plasma. 
Optimized magnetic microbubbles (MagMB) 
display high sensitivity to acoustic stimuli and 
visibility to ultrasonography  
To assess whether MagMB retained the 
microbubble’s sensitivity to ultrasound, we tested 
MagMB for acoustic destructibility and echogenicity. 
Acoustic destructibility was tested in vitro (Figure 4, 
A1) by exposing MagMB to acoustic insonations (1 
MHz, 0.22 MPa, 33 µs pulse duration and 3 kHz pulse 
repetition frequency) of varying durations (0-80 s). 
The profiles of acoustically-induced decay in particle 
 
Figure 3. Characterization of the optimized magnetic microbubbles, MagMB. A. Representative volume-weighted size distribution of MagMB dispersed 
in PBS, pH 7.4. B. Representative bright-field phase contrast micrographs of MagMB; inset - representative high magnification (100x) phase-contrast micrograph of 
MagMB. C. Representative TEM (I and II) and cryoTEM (III and IV) micrographs of MagMB. Micrographs I and III illustrate the composition of microbubbles and the 
multi-core structure of the MNPh nanoparticles, respectively. Micrographs II and IV illustrate attachment of nanoparticles to the microbubble’s surface. D. Analysis 
of MagMB stability in the presence of serum (50% FBS) as compared to PBS controls. Data represent mean ± SD, n = 4. Statistical comparison is based on unpaired 
t test; p = 0.07. CryoTEM: cryogenic transmission electron microscopy; FBS: fetal bovine serum; MagMB: magnetic microbubbles; MB: microbubbles; MNPh: magnetic 
nanoparticles coated with heparin; PBS: phosphate buffered saline; SD: standard deviation; TEM: transmission electron microscopy. 
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counts for MagMB (t1/2 = 18±3 s) did not differ 
significantly (p = 0.375) from those recorded for the 
FDA-approved microbubbles, Definity (t1/2 = 22±3 s), 
or from the control, non-magnetic MB-cnt (t1/2 = 16±4 
s) (Figure 4, A2). Previously reported formulations of 
magnetic microbubbles showed a significantly 
attenuated acoustic performance compared to 
clinically used contrast agents, likely due to the 
stiffening of the microbubble shell [11]. Unlike 
previous formulations, MagMB displayed 
Definity-like acoustic sensitivity demonstrating that 
they retained the acoustic properties of the 
microbubble contrast agents optimized for acoustic 
performance.  
 
 
Figure 4. Analysis of acoustic properties of MagMB. (A1) In vitro setup for assessing acoustic destructibility of microbubbles (full description of the setup is provided in 
methods, section “Acoustic destructibility assay”). (A2) Amenability of microbubble suspensions (107 /mL) to destruction by ultrasound: ‘US+’ =1 MHz tone-bursts of ultrasound 
insonation at 0.22 MPa peak negative pressure, 33 µs pulse duration, 3 kHz pulse repetition frequency and 0-80 s exposure time; ‘US-’ = no ultrasound insonation. Data represent 
mean ± SD, n = 4. (B1) In vitro setup for examining microbubble suspensions by B-mode ultrasonography. (B2) Representative B-mode ultrasonograms of MagMB, Definity and 
MBcnt suspensions in phosphate-buffered saline (106 /mL, PBS, pH 7.4); and a reference ultrasonogram of PBS solution. The images were acquired with a 30 MHz transducer at 
20% transmit power and 40 dB gain. Arrow depicts focal depth. (B3) In vitro echogenicity of microbubbles measured as background-normalized signal enhancement of PBS 
solution. Data represent mean ± SD, n = 4. (C1) Representative in vivo ultrasonograms demonstrating contrast enhancement of the renal artery by MagMB following i.v. bolus 
administration of the microbubbles (7.5x107 MB/kg, 100 µL) as compared to the baseline acquired prior to microbubble injection. The images were acquired with a 30 MHz 
transducer at 20% transmit power and 20 dB gain. (C2) In vivo echogenicity of microbubbles measured as background-normalized peak signal enhancement of renal artery. Data 
represent mean ± SD, n = 4. MB: microbubbles; PBS: phosphate buffered saline; RA: renal artery; SD: standard deviation; US: ultrasound. 
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We further compared the echogenicity of 
MagMB to that of Definity and MB-cnt using 
high-frequency (30 MHz) fundamental-mode 
ultrasonography. First, we examined B-mode 
ultrasonograms of microbubble suspensions in vitro 
(Figure 4, B1-B2). The in vitro echogenicity of MagMB 
(4.6±0.6) did not differ significantly (p = 0.68) from 
that produced by MB-cnt (5.0±0.7) or Definity (4.6±0.6; 
Figure 4, B3). We next examined the echogenicity of 
MagMB in vivo by measuring contrast enhancement of 
renal artery after an i.v. bolus dose of microbubbles 
(7.5x107 MB/kg, Figure 4, C1). Similar to the in vitro 
results, the in vivo echogenicity of MagMB (2.0±0.3) 
did not differ significantly (p = 0.97) from that 
produced by MB-cnt (1.9±0.5) or Definity (1.9±0.3; 
Figure 4, C2). Because echogenicity of lipid-shelled 
microbubbles is a manifestation of their 
compressibility, high Definity-like echogenicity of 
MagMB provided evidence that MagMB, unlike 
previously reported formulations, retained the 
original compressibility of “true” gaseous 
microbubbles coated with a phospholipid monolayer 
shell (such as Definity and MB-cnt) [6, 11].  
The ability of lipid-shelled microbubbles (e.g., 
Definity) to evade lung entrapment and circulate 
systemically has been ascribed to their compressibility 
and surface protection by stealth coatings [5, 26]. A 
combination of properties displayed by the MagMB 
including compressibility, surface protection with 
stealth heparin and stability in serum suggested that 
MagMB may be able to emulate the in vivo behavior of 
the original lipid-shelled microbubbles and circulate 
systemically. 
MagMB circulate systemically and evade 
entrapment in the lungs 
To examine the in vivo performance of MagMB, 
we assessed their biodistribution and 
pharmacokinetics. To study biodistribution, we 
labeled MagMB with a near infrared dye Cy5.5 
(MagMB-Cy5.5). At 30 min after i.v. bolus 
administration of MagMB-Cy5.5, the majority of 
Cy5.5 dose (68±11 %dose/g tissue) was localized in 
the liver with a minor fraction found in the spleen 
(19±10 %dose/g tissue, Figure 5, A1-A2). Importantly, 
the lungs were found to contain a very low fraction of 
the dose (7±5 %dose/g tissue). This fraction 
corresponded to ~1% of the Cy5.5 dose per total mass 
of the lung tissue (~0.5% per each lung) and was 17- to 
90-fold lower than the fraction of the dose reported to 
be entrapped in the lungs with previous magnetic 
microbubble formulations [11, 14]. These findings 
suggested that, in contrast to previous formulations, 
MagMB could successfully evade entrapment in 
pulmonary capillaries.  
We also explored whether an undesirable 
entrapment in the lungs could have occurred at earlier 
time points post administration. Previous studies 
demonstrated that composite microbubbles are 
initially entrapped in lung capillaries and then 
redistribute to the liver [14, 25]. To examine this 
possibility, we performed kinetic monitoring of the 
MagMB-Cy5.5 biodistribution using fluorescence 
imaging over the time interval of 2-30 min 
post-injection (Figure 5, C1-C2). At 2 min post 
injection, the lungs displayed negligible fluorescence, 
while the average fluorescence signal in the liver was 
a 1.5-fold higher than in the lungs. Over the 
subsequent time interval of 2-30 min post injection, 
the lungs showed no significant changes in 
fluorescent signal, ruling out the possibility of early 
lung entrapment followed by subsequent 
redistribution to the liver. In contrast, the liver 
exhibited a gradual increase in fluorescence over time 
that culminated in a plateau at 15 min post 
administration. These observations corroborated that 
the MagMB evaded lung entrapment and suggested 
that hepatic clearance was the main mechanism of 
MagMB elimination. The accumulation of MagMB in 
the liver displayed mono-exponential recovery 
kinetics with a half-life of 3.6±0.9 min, suggesting that 
MagMB circulated systemically (Figure 5, C2). 
We next evaluated the pharmacokinetics of 
MagMB. We used ultrasonography (30 MHz, 
fundamental mode) to monitor MagMB-induced 
contrast enhancement in the renal artery as a relative 
measure of MagMB concentrations in systemic 
circulation. Similar ultrasonographic procedures were 
previously utilized to assess the pharmacokinetics of 
echogenic microbubbles. [45] After an i.v. bolus dose 
of MagMB (1x109 /kg), signal enhancement of the 
renal artery could be detected for up to 13.3±0.9 min 
post injection, revealing that MagMB persisted in 
systemic circulation (Figure 5, B1-B2). Elimination of 
MagMB exhibited a two-phase profile with an initial 
faster phase responsible for the majority of MagMB 
clearance (>70% of area-under-the-curve) and a 
slower terminal phase. The half-life of the initial 
elimination phase was 2.8±0.8 min, which is 
comparable with the half-lives of clinically employed 
lipid-shelled microbubbles (Definity, 1.2-3 min) [45].  
Circulating MagMB can be accumulated in 
tumors by magnetic targeting, monitored by 
ultrasonography and collapsed by ultrasound 
To study the behavior of MagMB in tumors, we 
monitored MagMB transit through the tumor by 
ultrasonography (30 MHz, fundamental mode). The 
animals were positioned within the custom- 
assembled setup for magneto-acoustic targeting and 
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ultrasonography monitoring (Figure 6, A1-A3). The 
image field of view was aligned with the mid-plane 
tumor cross-section that passes through the 
geometrical center of the tumor (Figure 6, A4-A5). 
We first examined the MagMB performance in 
control mice that were not subjected to external 
physical triggers (Figure 6, B – control). Following i.v. 
bolus administration of MagMB (1x109 /kg), the 
tumor ROI in control mice displayed a detectable 
signal enhancement at about 5-10 s post injection, 
reaching a peak value (7.7±0.9 a.u) at 1 min post 
injection (Figure 6, C:top panel, D:blue curve). This 
value corresponded to ~13% of the mean signal 
enhancement (at the peak) observed in the renal 
artery (60±9 a.u.). Because the vascular space of 
subcutaneous tumor allografts in mice accounts for 
~15% of the total tumor volume [46], these findings 
indicated vascular confinement of MagMB within the 
tumor and reflected perfusion of the tumor with 
echogenic MagMB. Following the peak at 1 min 
post-injection, the signal enhancement in the tumor 
ROI dissipated rapidly consistent with the rapid 
elimination of MagMB from systemic circulation. 
Similar tumor elimination profile was also observed 
by fluorescence imaging following administration of 
MagMB-Cy5.5 (Figure S4). The duration of signal 
enhancement in the tumor ROI did not significantly 
differ from the duration of signal enhancement in the 
renal artery ROI (15±1 min vs. 13.3±0.9 min, p=0.09) 
indicating that MagMB were not retained in tumors of 
control animals. 
 
 
Figure 5. In vivo pharmacokinetics and biodistribution of MagMB. (A1) Organ biodistribution of MagMB-Cy5.5 quantified ex vivo by fluorescence 
spectrophotometry 30 min post administration. Data represent mean ± SD, n = 4. (A2) Representative qualitative biodistribution profiles of MagMB-Cy5.5 analyzed 
by fluorescence imaging 30 min post-administration. Lg: lungs; L: liver; K: kidneys; H: heart; S: spleen; T: tumor. Color bar represents fluorescence radiant efficiency 
expressed in [photon/s/cm2/steradian]/[μW/cm2]. (B1) Ultrasonography-based pharmacokinetics of MagMB, measured as mean contrast enhancement of renal 
artery over time (30 MHz, fundamental mode). Data represent mean ± SD, n = 4. (B2) Representative ultrasonograms of renal artery at different time points after i.v. 
bolus injection of MagMB (1x109 /kg); images depict overlays of contrast-enhancement maps over anatomical B-mode scans. Renal artery is identified by white arrows. 
The color bar represents contrast enhancement in arbitrary units. A.u: arbitrary units (C1) Representative kinetic sequence of the MagMB-Cy5.5 organ distribution 
analyzed by in vivo whole-body fluorescence imaging over a 30 min time interval post administration. The color bar represents fluorescence radiance expressed in 
[photon/s/cm2/steradian]. (C2) Average radiance sequentially analyzed for the liver and the lung ROIs over a 30 min time interval post MagMB-Cy5.5 administration. 
Data represent mean ± SD, n = 4. ROI: region of interest; SD: standard deviation.  
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Figure 6. In vivo magneto-acoustic modulation of MagMB monitored by ultrasonography. (A1) Schematic depiction of the setup for magneto-acoustic tumor targeting and 
ultrasonographic monitoring. The flank tumor is positioned in the air-gap between the poles of a dipole electromagnet. The actuating ultrasound transducer (1 MHz) and the ultrasound imaging 
transducer (30 MHz) are aligned orthogonally along the z and y dimensions. The actuating transducer is driven by a wavefunction generator and a radio frequency amplifier. The images are 
acquired by an ultrasound imaging system. FUS: focused ultrasound; M: magnet; RF amp: radio frequency amplifier; T: tumor; US: ultrasound; USi: ultrasound imaging; USIS: ultrasound imaging 
system; WG: wavefunction generator. (A2) Top view of the setup: demonstrates the tumor positioning within the magnet and the alignment of the imaging probe relative to the tumor and the 
magnetic field. The coordinates (0,0,0) represent the geometrical tumor center. (A3) Magnetic field topography generated by the dipole electromagnet. (A4) Representative ultrasonogram of 
the tumor cross-section acquired using the probe alignment depicted in A2. (A5) Schematic depiction of the image field of view: image field of view is aligned with the mid-plane tumor 
cross-section that passes through the geometrical tumor center (0,0,0). (B) Time-line of the magnetic targeting and ultrasound treatments following MagMB administration. MagMB: magnetic 
microbubbles; MF: magnetic field; US: ultrasound. (C) Representative ultrasonograms of the tumor at different time points after i.v. bolus injection of MagMB (1x109 /kg) without (top panel, 
MF-, US-) and with (bottom panel) application of magnetic field (MF+: t = 0-30 min, 0.9 T, 50 T/m) and ultrasound (US+: t = 40 min, 1 MHz, PNP = 0.22 MPa, PD = 33 µs, PRF = 3 kHz, exposure 
time = 50 s). Images depict overlays of contrast-enhancement maps over anatomical B-mode scans. The color bar represents contrast enhancement in arbitrary units. A.u.: arbitrary units; PD: 
pulse duration; PNP: peak negative pressure; PRF: pulse repetition frequency. (D) Kinetics of MagMB transit through the tumor without (blue) and with (black) application of magnetic field 
(MF+: t = 0-30 min, 0.9 T, 50 T/m) and ultrasound (US+: t = 40 min, 1 MHz, PNP = 0.22 MPa, PD = 33 µs, PRF = 3 kHz, exposure time = 50 s). Data represents mean contrast enhancement 
within the tumor ROI in arbitrary units; mean ± SD, n = 4. (E) Comparison of mean contrast enhancement within the tumor ROI at 1 min and 5 min post-administration of MagMB with (MF+) 
and without (MF-) application of magnetic field. Statistical analysis is based on a one-way ANOVA, followed by post hoc Tukey’s pairwise comparisons. Asterisks denote statistically significant 
differences, *p < 0.05, **p < 0.01, ***p < 0.001, N.S.: p>0.05. ANOVA: analysis of variance; N.S.: not significant; ROI: region of interest; SD: standard deviation.  
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We next asked whether MagMB could be 
amenable to magnetic targeting. Application of 
magnetic field (B = 0.9 T, grad B = 50 T/m) to tumor 
lesions of mice after i.v. bolus of MagMB (1x109 /kg) 
significantly altered the kinetics and the magnitude of 
ultrasonographic signal enhancement compared to 
controls (Figure 6, C: bottom panel, D: black curve). 
Following the initial wash-in phase, the signal in the 
tumor ROI of magnetically targeted animals 
displayed a gradual increase and reached a plateau at 
5 min post injection. This plateau-level contrast 
enhancement persisted for the entire duration of 
magnetic targeting (up to 30 min). Overall, the signal 
enhancement in magnetically targeted animals 
reached a significantly higher magnitude than in 
controls (11.8±0.6 a.u. vs. 7.7±0.9 a.u., p=0.02) and 
exhibited a significantly longer duration than in 
controls (30±2 min vs. 15±1 min, p<0.001). Notably, at 
30 min post injection, the signal enhancement in 
magnetically targeted animals was 15-fold higher 
than in controls (12±2 a.u. vs. 0.7±0.8 a.u., p=0.03). 
These findings demonstrated that MagMB could be 
magnetically accumulated and retained in the tumor. 
We also asked whether the magnetically 
captured MagMB retained their amenability to 
acoustic collapse. We exposed the tumors of 
magnetically targeted animals to ultrasound. A brief 
(50 s, ~3 half-lives) acoustic exposure (1 MHz, PNP = 
0.22 MPa, PD = 33 µs, PRF = 3 kHz) was sufficient to 
collapse magnetically captured MagMB, as reflected 
by a rapid signal decay within the tumor ROI (Figure 
6, C: bottom panel, D: black curve t > 40 min). This 
result indicated that magnetically captured 
microbubbles indeed retained their acoustic 
sensitivity, and were amenable to both the magnetic 
and the acoustic modulation in vivo. 
Drug delivery to tumors using MagMB can be 
enhanced by adjusting the magneto-acoustic 
targeting based on real-time monitoring of 
MagMB by ultrasonography 
We evaluated the potential of MagMB to 
improve drug delivery to tumors. We assessed 
delivery of a model drug Cy5.5 using MagMB-Cy5.5 
as a delivery platform and evaluated the feasibility of 
modulating delivery by a combination of magnetic 
targeting and ultrasound (Figure 7). Ultrasound- 
triggered microbubble destruction (UTMD) has been 
extensively investigated as a drug-targeting 
mechanism because of its ability to simultaneously 
release the microbubble-loaded drug and promote its 
access to tissue parenchyma of the target tissue [5, 8]. 
However, low efficiency of this mechanism limits its 
translational potential. Previous work demonstrated 
that the UTMD efficiency can be increased by 
increasing local microbubble concentration at the 
target site with local microbubble injections [47]. We 
asked whether concentrating the MagMB-Cy5.5 in 
tumor vasculature by magnetic targeting prior to 
applying UTMD could similarly improve the drug 
delivery efficiency with systemic microbubble 
administration.  
First, we subjected mice to a combination of 
magnetic targeting and UTMD (magneto-acoustic 
targeting), applying magnetic targeting for 1 min 
(Figure 7, A). The level of tumor fluorescence in mice 
achieved with this procedure (at 120 min post 
treatment) did not differ significantly from the levels 
achieved with the UTMD alone (Figure 7B-C, 2.6±0.4 x 
108 photon/s vs. 2.5±0.3 x 108 photon/s, p=0.91). These 
results suggested that 1 min duration of magnetic 
targeting may have not been sufficient to concentrate 
MagMB in tumor vasculature. This result was 
consistent with the ultrasonography observations, 
which revealed that application of magnetic targeting 
for 1 min did not significantly enhance the 
accumulation of MagMB in tumor vasculature 
compared to controls not subjected to magnetic 
targeting (Figure 6D, 7±2 a.u. vs. 8±2 a.u., p=0.92).  
Ultrasonographic monitoring of MagMB 
suggested that MagMB accumulation in the tumor by 
magnetic targeting occurs gradually over time (Figure 
6D). We asked whether real-time ultrasonographic 
information on kinetics of the MagMB accumulation 
in the tumor could be leveraged to optimize drug 
delivery. Based on ultrasonographic monitoring, 
MagMB could be concentrated in the tumor to a 
significantly higher extent by 5 min of magnetic 
targeting than by 1 min of magnetic targeting (Figure 
6D-E, 11.8±0.6 a.u. vs. 7±2 a.u., p=0.01). We therefore 
explored the effect of magneto-acoustic targeting on 
drug delivery when applying magnetic targeting for 5 
min. Indeed, with 5 min of magnetic targeting, a 
2-fold higher tumor fluorescence was observed in 
magneto-acoustically targeted mice than in mice 
subjected to the UTMD alone (Figure 7B-C, 4.1±0.4 x 
108 photon/s vs. 1.9±0.3 x 108 photon/s, p<0.01). These 
results revealed that combining UTMD with magnetic 
targeting can indeed enhance the drug targeting 
efficiency by UTMD, provided that magnetic 
targeting is applied for sufficient time to concentrate 
the MagMB in tumor vasculature. Importantly, these 
findings also demonstrated that non-invasive 
ultrasonography could provide the required kinetic 
information on MagMB accumulation in the tumor, 
allowing real-time adjustment of the magnetic 
targeting and UTMD to enhance drug delivery. 
Notably, although MagMB could be 
accumulated in the tumor by magnetic targeting 
alone, as evident from the ultrasonography results 
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(with 5 min of magnetic targeting), Cy5.5 delivery to 
tumors with magnetic targeting alone did not differ 
significantly from non-targeted controls (Figure 7B-C, 
0.5±0.4 x 108 photon/s vs. 0.1±0.2 x 108 photon/s, 
p=0.72). While ultrasonographic monitoring of 
MagMB accumulation in the tumor by magnetic 
targeting was carried out in real-time, the 
fluorescence measurements of drug delivery were 
performed 120 min post treatment (Figure 7A). Thus, 
the apparent discrepancy is likely attributed to the 
reversal of magnetic holding of MagMB-Cy5.5 with 
the removal of the magnetic field. Similar reversal of 
magnetic carrier entrapment with the removal of the 
magnetic field has been reported in previous studies. 
[34] Our ultrasonography results demonstrating the 
decay of ultrasonographic contrast enhancement by 
magnetically-entrapped MagMB following removal of 
magnetic field are consistent with this behavior 
(Figure 6D, time interval 30<t<40 min). In contrast to 
magnetic targeting alone, the UTMD component of 
the combined magneto-acoustic targeting has likely 
promoted the extravasation of the released drug 
Cy5.5 into the tumor parenchyma, prolonging its 
residence within the tumor. Mechanical forces 
associated with microbubble collapse by ultrasound 
(e.g., shock waves, sonic jets) have been shown to 
increase permeability of the vascular barrier and 
propel drug-containing fragments of the 
microbubble’s shell into the tissue parenchyma.[8, 48, 
49] Similar phenomena are likely responsible for the 
prolonged residence of Cy5.5 in tumors exposed to 
the UTMD in our studies, but further work is required 
to elucidate the mechanism.  
 
 
Figure 7. In vivo delivery of a model drug Cy5.5 to tumors using MagMB-Cy5.5 and magneto-acoustic modulation. (A) Time-line of the magnetic 
targeting and ultrasound treatments following MagMB-Cy5.5 administration and the subsequent drug delivery evaluation by fluorescence imaging. FL: fluorescence; 
MagMB: magnetic microbubbles; MF: magnetic field; US: ultrasound. (B) Representative qualitative biodistribution profiles of Cy5.5 analyzed by fluorescence imaging 
120 min post administration of MagMB-Cy5.5 under different modulation conditions: (MF-, US-) no magnetic targeting or ultrasound, (MF+, US-) magnetic targeting 
only, (MF-, US+) ultrasound only, (MF+, US+) combination of magnetic targeting and ultrasound. Magnetic targeting (MF+: 0.9 T, 50 T/m) was applied for 1 min (top 
row) or 5 min (bottom row), immediately followed by ultrasound (US+: 1 MHz, PNP = 0.22 MPa, PD = 33 µs, PRF = 3 kHz) for 50 s. MF: magnetic field; PD: pulse 
duration; PNP: peak negative pressure; PRF: pulse repetition frequency; US: ultrasound. Color bar represents fluorescence radiant efficiency expressed in 
[photon/s/cm2/steradian]/[μW/cm2]. (C) Comparison of total fluorescence flux within the tumor ROI (photon/s) achieved under experimental conditions in B. The 
fluorescence flux of test animals in all groups was background corrected by subtracting the tumor ROI flux of blank controls – animals not exposed to MagMB-Cy5.5. 
Data represent mean ± SD, n = 4. Statistical analysis is based on a one-way ANOVA, followed by post hoc Tukey’s pairwise comparisons. Asterisks denote statistically 
significant differences: *p < 0.05, **p < 0.01, ***p < 0.001. ANOVA: analysis of variance; ROI: region of interest; SD: standard deviation. 
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Conclusions 
Taken together, we demonstrate the feasibility of 
leveraging magnetic microbubbles to enhance drug 
delivery to tumors by first magnetically concentrating 
these agents in tumor vasculature and then applying 
ultrasound to facilitate microbubble collapse. To 
realize this paradigm, we developed circulating 
magnetic microbubbles (MagMB) that exhibit strong 
magnetic and acoustic activities while also preserving 
circulation stability. Unlike previously reported 
magnetic microbubbles, MagMB evaded lung 
entrapment and could circulate systemically, which is 
likely due to the preserved compressibility of their 
lipid shell and surface protection with stealth heparin. 
We demonstrate that MagMB could reach tumor 
vasculature after systemic administration, allowing 
their modulation with magnetic and acoustic 
forcefields selectively in target tumors. 
Ultrasonographic monitoring of MagMB in tumor 
vasculature provided real-time information on the 
extent of microbubble accumulation by magnetic 
targeting and could be leveraged to time magnetic 
and ultrasonic actuation components for achieving 
drug delivery enhancement. MagMB could 
potentially be leveraged as a carrier for a wide variety 
of small molecule drugs. For example, for application 
in cancer therapy the therapeutic cargo could 
comprise chemotherapeutic drugs, sonosensitizers or 
immunomodulating agents. [40, 50-52] Overall, 
magnetic microbubbles (MagMB) in conjunction with 
ultrasound-guided magneto-acoustic modulation 
may provide a strategy for tailored minimally 
invasive control over delivery of therapeutic 
molecules to tumors and other target tissues. This 
approach warrants further investigation for 
development of tailored therapeutic strategies with 
improved efficacy and safety. 
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